Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity

Journal of Clinical Oncology

Volumn 23, Issue 7, 2005, Pages 1365-1369

  Jakobsen, Anders ^a   Nielsen, Jens Nederby ^a   Gyldenkerne, Niels ^a   Lindeberg, Jan ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FLUOROURACIL; FOLINIC ACID; THYMIDYLATE SYNTHASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; ADVANCED CANCER; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; COLORECTAL TUMOR; DISEASE COURSE; DRUG SCREENING; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE;

EID: 14944380124     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.219     Document Type: Article

References (20)

1. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
2. Marsh S, McKay JA, Cassidy J, et al: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19:383-386, 2001
3. Kawakami K, Salonga D, Park JM, et al: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7:4096-4101, 2001
4. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65-70, 2001
5. Tsuji T, Hidaka S, Sawai T, et al: Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 9:3700-3704, 2003
6. Frosst P, Blom HJ, Milos R, et al: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113, 1995
7. Sohn KJ, Croxford R, Yates Z, et al: Methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96:134-144, 2004
8. Jakobsen A, Berglund A, Glimelius B, et al: Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. Acta Oncol 41:525-531, 2002
9. Iacopetta B, Grieu F, Joseph D, et al: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85:827-830, 2001
10. Skibola CF, Smith MT, Kane E, et al: Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 96:12810-12815, 1999
11. Etienne MC, Chazal M, Laurent-Puig P, et al: Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: Phenotypic and genotypic analyses. J Clin Oncol 20:2832-2843, 2002
12. Villafranca E, Okruzhnov Y, Dominguez MA, et al: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19:1779-1786, 2001
13. Uchida K, Hayashi K, Kawakami K, et al: Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 10:433-439, 2004
14. Ishida Y, Kawakami K, Tanaka Y, et al: Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res 22:2805-2809, 2002
15. Kornmann M, Schwabe W, Sander S, et al: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: Predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9:4116-4124, 2003
16. Edler D, Glimelius B, Hallstrom M, et al: Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20:1721-1728, 2002
17. Sobrero A, Aschele C, Bertino JR: Fluorouracil in colorectal cancer: A tale of two drugs-Implications for biochemical modulation. J Clin Oncol 15:368-381, 1997
18. Glimelius B, Jakobsen A, Graf W, et al: Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: A prospective randomised trial. Eur J Cancer 34:674-678, 1998
19. Cohen V, Panet-Raymond V, Sabbaghian N, et al: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9:1611-1615, 2003
20. Etienne MC, Ilc K, Formento JL, et al: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: Relationships with 5-fluorouracil sensitivity. Br J Cancer 90:526-534, 2004